Mental Disorders

274 trials 116 recruiting

Filter these 274 trials by phase, country and sponsor.

Open in Search →

Investigation of neurobiological mechanisms of antidepressant action of ketamine using neuroimaging Recruiting

2024-519234-23-00 Healthy volunteers - no medical condition 3 2020-01-17
An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficac… Recruiting

2024-519237-34-00 Treatment for Refractory Schizophrenia in Adults 10 2019-11-26
A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injec… Recruiting

2024-513022-29-00 Major Depression Disorders 5 2019-01-09
A Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Gen… Ended

2024-513572-17-00 Generalized Anxiety Disorder (GAD) 5 2025-08-20
HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuatio… Ended

2024-518769-80-00 HAMLETT compares regular treatment guidelines for patie 6 2024-11-25
Trial Examining Methods for Antidepressant Discontinuation (TEMPO) Ended

2024-511997-66-00 Major Depressive Disorder 6 2024-11-22
Antidepressant effects of psilocybin in pharmaco-resistant depression Ended

2024-515899-13-00 pharmaco-resistant depression 4 2024-11-21
Evaluation of the effect of a single dose of psilocybin on neural correlates of cognitive control in patients with CNEP (psychogenic nonepil… Ended

2023-509679-17-00 psychogenic non-epileptic seizures 4 2024-11-05
Maternal Mental Health (MAMA) Study. Short time treatment with female sex hormone to prevent postpartum depression in a high-risk group Ended

2024-518028-63-00 Perinatal depression with postpartum onset 4 2024-10-08
Long-term Study to Assess the Safety and Effectiveness of NMRA-335140 in Participants with Major Depressive Disorder Ended

2023-505892-56-00 Major Depressive Disorder 5 2024-09-30
A randomized controlled trial with Rituximab for Psychotic disorder in adults Ended

2024-512408-20-00 Schizophrenia spectrum disorder (SSD) 4 2024-08-27
A prospective randomized, single blind, controlled, safety and non-inferiority study of esketamine plus propofol compared to methohexital an… Ended

2024-512210-18-00 major depression 11 2024-08-01
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
A study to see how well KarXT works and how well tolerated it is in participants with psychosis associated with Alzheimer’s disease. Ended

2023-504416-16-00 Psychosis Associated with Alzheimer’s Disease 5 2024-04-11
A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended

2023-505268-12-00 Treatment-resistant depression 5 2024-02-09
Pramipexole in depression - a follow-up study Ended

2022-502270-17-00 Depression 5 2023-04-21
Adjuvant treatment with Pramipexole for anhedonia symptoms in depression - PRIME-PRAXOL Ended

2024-512495-35-00 Major depression 5 2022-10-16
Morphine effects on stress response and social interaction – an exploratory randomized controlled experimental medicine study Ended

2024-517855-10-00 Healthy volunteers 4 2022-04-20
Please refer to the full title. Ended

2024-516549-37-00 Treatment of Parkinson’s disease (PD) 4 2021-04-12
Research into the effects of the drug DMT in healthy volunteers Halted

2025-521605-40-00 major depressive disorder (MDD) 3 2025-06-10
CAPSI - Cancer related major depression treated with a single dose of psilocybin - a multicenter randomized placebo controlled double blind … Halted

2023-505532-35-00 Malignant tumours ICD 10 C00 to C97 4 2024-05-15
Enhancing recovery in early schizophrenia: A study comparing cannabidiol and placebo as add-on to standard antipsychotic treatment. Halted

2024-517198-26-00 Remitted early phase schizophrenia 4 2017-02-17
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexa… Ended

2025-521224-29-00 ADHD (Attention Deficit Hyperactivity Disorder) 2 2026-02-20
A double blinded, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, bioequivalence study comparing Bupr… Ended

2024-516035-27-00 major depressive illness 2 2026-01-09